Andrew Zolopa

9.6k citations
107 papers · 6.9k · 2 hit papers · h-index 43

Impact in

  • Virology top 0.1%
    • HIV Research and Treatment
  • Infectious Diseases top 0.1%
    • HIV/AIDS Research and Interventions
    • HIV/AIDS drug development and treatment

Papers in

  • Infectious Diseases 91
    • HIV/AIDS drug development and treatment 75
    • HIV/AIDS Research and Interventions 60
  • Virology 70
    • HIV Research and Treatment 70
Co-authors
Andrew R. Moss (4 shared papers)David R. Bangsberg (3 shared papers)Edwin D. Charlebois (3 shared papers)Robert W. Shafer (21 shared papers)Richard A. Clark (2 shared papers)Sharon Perry (2 shared papers)Mark Holodniy (5 shared papers)Lewis B. Sheiner (1 shared paper)
Journals
JAIDS Journal of Acquired Immune Deficiency Syndromes (15 papers)AIDS (10 papers)The Journal of Infectious Diseases (10 papers)Antimicrobial Agents and Chemotherapy (10 papers)Open Forum Infectious Diseases (8 papers)
Partner nations
United StatesUnited KingdomFrance

In The Last Decade

Andrew Zolopa

104 papers receiving 6.7k citations

Andrew Zolopa's Hit Papers

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS 2001 · 785 citations
7850+8+17Years since publication250500750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2001 AIDS
  2. 2000 AIDS

Peers

Andrew Zolopa
Comparison fields: 5 of 140
  • Virology 3.6k
  • Infectious Diseases 5.6k
  • Emergency Medicine 1.3k
  • Family Practice 135
  • Epidemiology 1.9k
Replace Diane Aschman with:
Diane Aschman United States
Mark O. Loveless United States
François Raffi France
Jack Fuhrer United States
Kelly A. Gebo United States
Judith Feinberg United States
Enos Bernasconi Switzerland
Richard Haubrich United States
Peter L. Anderson United States
Robert T. Schooley United States
Andrew Zolopa relative to Diane Aschman United States Diane Aschman's profile →
Citations per field
00.5×1.5×2×2.4×
Diane Aschman · 1×
Citations per year

Countries citing papers authored by Andrew Zolopa

Since Specialization
Citations

This map shows the geographic impact of Andrew Zolopa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Zolopa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Zolopa more than expected).

Fields of papers citing papers by Andrew Zolopa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Zolopa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Zolopa. The network helps show where Andrew Zolopa may publish in the future.

Co-authors

The 25 scholars most cited alongside Andrew Zolopa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew Zolopa Line = papers co-authored together Andrew Zolopa links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 107 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
AIDS ·David R. Bangsberg, Frederick Hecht, Edwin D. Charlebois, Andrew Zolopa, Mark Holodniy, Lewis B. Sheiner, Joshua D. Bamberger, Margaret A. Chesney, Andrew R. Moss
Hit paper breakdown →		2000864
2
Non-adherence to highly active antiretroviral therapy predicts progression to AIDS
AIDS ·David R. Bangsberg, Sharon Perry, Edwin D. Charlebois, Richard A. Clark, Marjorie Roberston, Andrew Zolopa, Andrew R. Moss
Hit paper breakdown →		2001785
3
Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial
PLoS ONE ·Andrew Zolopa, Janet Andersen, Lauren Komarow, Ian Sanne, Alejandro Sanchez, Evelyn Hogg, Carol Suckow, William G. Powderly, (unknown)
2009382
4
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
The Lancet ·Paul E. Sax, Edwin DeJesus, Anthony Mills, Andrew Zolopa, Calvin Cohen, David A. Wohl, Joel E. Gallant, Hui C. Liu, Lijie Zhong, Kitty Yale, Kirsten White, Brian P. Kearney, Javier Szwarcberg, Erin Quirk, Andrew Cheng
2012335
5
Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM Study Cohort
JAIDS Journal of Acquired Immune Deficiency Syndromes ·Phyllis C. Tien, Andy I. Choi, Andrew Zolopa, Constance A. Benson, Russell P. Tracy, Rebecca Scherzer, Peter Bacchetti, Michael G. Shlipak, Carl Grünfeld
2010225
6
HIV and Tuberculosis Infection in San Francisco's Homeless Adults
JAMA ·Andrew Zolopa
1994201
7
Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV‐1–Infected, Treatment‐Experienced Patients: AIDS Clinical Trials Group 5211
The Journal of Infectious Diseases ·Roy M. Gulick, Zhaohui Su, Charles Flexner, Michael D. Hughes, Paul R. Skolnik, Timothy Wilkin, Robert Gross, Amy Krambrink, Eoin Coakley, Wayne Greaves, Andrew Zolopa, Richard C. Reichman, Catherine Godfrey, Martin Hirsch, Daniel R. Kuritzkes
2007195
8
High levels of adherence do not prevent accumulation of HIV drug resistance mutations
AIDS ·David R. Bangsberg, Edwin D. Charlebois, Robert M. Grant, Mark Holodniy, Steven G. Deeks, Sharon Perry, Kathleen Conroy, Richard A. Clark, David Guzman, Andrew Zolopa, Andrew R. Moss
2003194
9
Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments
Journal of Virology ·Thomas D. Wu, Celia A. Schiffer, Matthew J. Gonzales, Jonathan Taylor, Rami Kantor, Sunwen Chou, Dennis Israelski, Andrew Zolopa, W. Jeffrey Fessel, Robert W. Shafer
2003194
10
HIV-1 Genotypic Resistance Patterns Predict Response to saquinavir–ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed
Annals of Internal Medicine ·Andrew Zolopa, Robert W. Shafer, Ann L. Warford, José G. Montoya, Phillip J. Hsu, David Katzenstein, Thomas C. Merigan, Brad Efron
1999176
11
Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy
JAIDS Journal of Acquired Immune Deficiency Syndromes ·Paul E. Sax, Andrew Zolopa, Indira Brar, Richard Elion, Roberto Ortiz, Frank A. Post, Hui Wang, Christian Callebaut, Hal Martin, Marshall W. Fordyce, Scott McCallister
2014165
12
HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance
Antimicrobial Agents and Chemotherapy ·Soo‐Yon Rhee, Jonathan Taylor, W. Jeffrey Fessel, David R. Kaufman, William Towner, Paolo Troia, Peter Ruane, James Hellinger, Vivian Shirvani, Andrew Zolopa, Robert W. Shafer
2010153
13
A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection
JAIDS Journal of Acquired Immune Deficiency Syndromes ·Andrew Zolopa, Paul E. Sax, Edwin DeJesus, Anthony Mills, Calvin Cohen, David A. Wohl, Joel E. Gallant, Hui C. Liu, Andrew Plummer, Kirsten White, Andrew Cheng, Martin S. Rhee, Javier Szwarcberg
2013122
14
Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection
PLoS ONE ·Philip Grant, Lauren Komarow, Janet Andersen, Irini Sereti, Savita Pahwa, Michael M. Lederman, Joseph J. Eron, Ian Sanne, William G. Powderly, Evelyn Hogg, Carol Suckow, Andrew Zolopa
2010119
15
Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial
The Journal of Infectious Diseases ·Andrew Zolopa, Daniel S Berger, Harry Lampiris, Lijie Zhong, Steven L. Chuck, Jeffrey Enejosa, Brian P. Kearney, Andrew Cheng
2010103
16
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults
Journal of Antimicrobial Chemotherapy ·Martin Markowitz, Andrew Zolopa, K. Squires, Peter Ruane, Dion F. Coakley, Brian P. Kearney, Lijie Zhong, Michael Wulfsohn, Michael D. Miller, W. A. Lee
2014103
17
HIV‐1 Protease and Reverse‐Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug‐Resistance Surveillance
The Journal of Infectious Diseases ·Soo‐Yon Rhee, W. Jeffrey Fessel, Andrew Zolopa, Leo B. Hurley, Tommy Liu, Jonathan Taylor, Dong Phuong Nguyen, Sally Slome, Daniel B. Klein, Michael A. Horberg, Jason Flamm, Stephen Follansbee, Jonathan Schapiro, Robert W. Shafer
200594
18
Antiviral Activity of Lamivudine in Salvage Therapy for Multidrug‐Resistant HIV‐1 Infection
Clinical Infectious Diseases ·Thomas Campbell, Nancy S. Shulman, Steven C. Johnson, Andrew Zolopa, Russell K. Young, Lane R. Bushman, Courtney V. Fletcher, E. Randall Lanier, Thomas C. Merigan, Daniel R. Kuritzkes
200594
19
Evidence for Genetic Regulation of Susceptibility to Toxoplasmic Encephalitis in AIDS Patients
The Journal of Infectious Diseases ·Yasuhiro Suzuki, Sin-Yew Wong, F. Carl Grumet, Jeffrey Fessel, José G. Montoya, Andrew Zolopa, Amy Portmore, F. Schumacher-Perdreau, Matthias Schrappe, Sofie van Koppen, B. Ruf, Byron W. Brown, J S Remington
199693
20
Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors
AIDS ·Matthew J. Gonzales, Thomas D. Wu, Jonathan Taylor, Ilana Belitskaya, Rami Kantor, Dennis Israelski, Sunwen Chou, Andrew Zolopa, W. Jeffrey Fessel, Robert W. Shafer
200389

About Andrew Zolopa

Andrew Zolopa is a scholar working on Infectious Diseases, Virology, Epidemiology, Emergency Medicine and Hepatology, having authored 107 papers that have together received 6.9k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (75 papers), HIV Research and Treatment (70 papers), HIV/AIDS Research and Interventions (60 papers), HIV-related health complications and treatments (18 papers), Pneumocystis jirovecii pneumonia detection and treatment (16 papers), Hepatitis C virus research (11 papers), HIV, Drug Use, Sexual Risk (7 papers) and Pharmacological Effects and Toxicity Studies (5 papers). The work is most often cited by research in Virology (3.6k citations), Infectious Diseases (5.6k citations), Emergency Medicine (1.3k citations), Family Practice (135 citations) and Epidemiology (1.9k citations). Andrew Zolopa has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Andrew R. Moss, David R. Bangsberg, Edwin D. Charlebois, Robert W. Shafer, Richard A. Clark, Sharon Perry, Mark Holodniy, Lewis B. Sheiner, Margaret A. Chesney and Joshua D. Bamberger. Their work appears in journals such as JAIDS Journal of Acquired Immune Deficiency Syndromes, AIDS, The Journal of Infectious Diseases, Antimicrobial Agents and Chemotherapy and Open Forum Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Diane AschmanBreakdown of academic impact, for papers by Mark O. LovelessBreakdown of academic impact, for papers by François RaffiBreakdown of academic impact, for papers by Jack FuhrerBreakdown of academic impact, for papers by Kelly A. GeboBreakdown of academic impact, for papers by Judith FeinbergBreakdown of academic impact, for papers by Enos BernasconiBreakdown of academic impact, for papers by Richard HaubrichBreakdown of academic impact, for papers by Peter L. AndersonBreakdown of academic impact, for papers by Robert T. Schooley